Monopar Therapeutics (MNPR) Invested Capital (2016 - 2020)
Historic Invested Capital for Monopar Therapeutics (MNPR) over the last 5 years, with Q3 2020 value amounting to $17.6 million.
- Monopar Therapeutics' Invested Capital rose 27966.61% to $17.6 million in Q3 2020 from the same period last year, while for Sep 2020 it was $17.6 million, marking a year-over-year increase of 27966.61%. This contributed to the annual value of $12.6 million for FY2019, which is 8252.56% up from last year.
- Latest data reveals that Monopar Therapeutics reported Invested Capital of $17.6 million as of Q3 2020, which was up 27966.61% from $12.2 million recorded in Q2 2020.
- Monopar Therapeutics' Invested Capital's 5-year high stood at $17.6 million during Q3 2020, with a 5-year trough of $2.8 million in Q4 2016.
- In the last 5 years, Monopar Therapeutics' Invested Capital had a median value of $8.1 million in 2018 and averaged $8.8 million.
- In the last 5 years, Monopar Therapeutics' Invested Capital plummeted by 3895.16% in 2019 and then surged by 27966.61% in 2020.
- Over the past 5 years, Monopar Therapeutics' Invested Capital (Quarter) stood at $2.8 million in 2016, then surged by 239.78% to $9.6 million in 2017, then decreased by 28.08% to $6.9 million in 2018, then skyrocketed by 82.53% to $12.6 million in 2019, then surged by 39.05% to $17.6 million in 2020.
- Its Invested Capital was $17.6 million in Q3 2020, compared to $12.2 million in Q2 2020 and $12.4 million in Q1 2020.